Thus, a larger sample size is necessary in a multicenter randomised controlled clinical study to demonstrate the efficacy and safety of concurrent EGFR-TKI and TRT in advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.